IARTIntegra LifeSciences Holdings CorporationHealthcare · Medical - Devicesas of 2026-09-16
Horizon

Issued 2026-09-16 at $16.06 · now $16.06 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, IART has typically landed between $12.74 and $19.02 — a range of −20.7% to +18.4% from the issuance price $16.06.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

5,003 overlapping 1 month windows · 2006-09-26 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($16.06) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where IART has typically landed a month from the 2026-09-16 close of $16.06 — the range is history, not a prediction.

$12.74worst · -20.7%$19.02best · +18.4%
  • now $16.06 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $15.66 (-2.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $14.34–$16.98
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $12.74–$19.02
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 5,003 windows spanning 2006-09-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2020-02-21−38.1%−38.1%+0.0%
2020-02-19−37.9%−39.6%+0.0%
2020-02-20−37.5%−39.1%+0.0%
3 best
2026-04-29+59.1%+0.0%+63.3%
2026-04-28+53.3%−6.1%+53.3%
2024-10-08+52.7%+0.0%+52.7%

5,003 overlapping windows · 2006-09-26 – 2026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
45%
−1.0%
n=20
Feb
55%
+0.8%
n=20
Mar
50%
−0.4%
n=20
Apr
50%
+0.4%
n=20
May
55%
+1.2%
n=20
Jun
50%
+1.0%
n=20
Jul
65%
+1.7%
n=20
Aug
55%
−1.1%
n=20
Sep
25%
−2.5%
n=20
Oct
30%
−3.1%
n=20
Nov
80%
+4.2%
n=20
Dec
70%
+3.2%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$20$92025-11-05: 1 insider purchase, $102K — GRAVES JEFFREY A2025-11: 1 open-market purchase, $102K↑ buys↓ salesdirector GRAVES JEFFREY A — Purchase on 2025-11-05, filed 1 day after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2025-11-05GRAVES JEFFREY AdirectorPurchase9,000 @ $11.35$102K+28.0% of holding+14.9%+12.6%41,086Form 4 · filed 1 day after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

104 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-09-01Veillon-Berteloot ChantalofficerWithheld for tax1,45520,772Form 4
2026-07-03Knight Lea DanielsofficerWithheld for tax5,22645,263Form 4
2026-07-01Mosebrook JeffreyofficerWithheld for tax93734,516Form 4
2026-07-01DAVIS ROBERT T. JR.officerAward / grant11,18054,530Form 4
2026-07-01Singh HarvinderofficerAward / grant5,59068,883Form 4
2026-06-01McBreen Michael J.officerAward / grant31,909124,017Form 4
2026-06-01ESSIG STUARTdirectorAward / grant705,468705,468Form 4
2026-06-01ESSIG STUARTdirectorAward / grant365,297365,297Form 4
2026-06-01McBreen Michael J.officerAward / grant60,37260,372Form 4
2026-05-09BRADLEY KEITHdirectorWithheld for tax88288,254Form 4
2026-05-07SCHADE CHRISTIAN SdirectorAward / grant17,70017,700Form 4
2026-05-07Lo Renee WonlaidirectorAward / grant17,70017,700Form 4
2026-05-07GRAVES JEFFREY AdirectorAward / grant17,70017,700Form 4
2026-05-07HILL BARBARA BdirectorAward / grant6,638133,491Form 4
2026-05-07HILL BARBARA BdirectorAward / grant17,700151,191Form 4
2026-05-07Clay ShaundradirectorAward / grant17,70017,700Form 4
2026-05-07BRADLEY KEITHdirectorAward / grant17,70017,700Form 4
2026-03-11DAVIS ROBERT T. JR.officerWithheld for tax8,48766,387Form 4
2026-03-11Knight Lea DanielsofficerWithheld for tax8,08950,489Form 4
2026-03-11McBreen Michael J.officerWithheld for tax7,24760,743Form 4
2026-03-11Veillon-Berteloot ChantalofficerWithheld for tax5,42022,227Form 4
2026-03-11Singh HarvinderofficerWithheld for tax5,19035,422Form 4
2026-03-11Singh HarvinderofficerWithheld for tax86121,690Form 4
2026-03-11Mosebrook JeffreyofficerWithheld for tax80635,453Form 4
2026-03-11Hutchinson Michael DamonofficerAward / grant70,305159,911Form 4
2026-03-11Mosebrook JeffreyofficerAward / grant15,95715,957Form 4
2026-03-11Poul MojdehdirectorAward / grant343,393445,691Form 4
2026-03-11Singh HarvinderofficerOption exercise18,92240,612Form 4
2026-03-11DAVIS ROBERT T. JR.officerAward / grant43,35043,350Form 4
2026-03-11McBreen Michael J.officerAward / grant92,10892,108Form 4
2026-03-11Singh HarvinderofficerOption exercise2,35618,994Form 4
2026-03-11Singh HarvinderofficerOption exercise16,5662,428Form 4
2026-03-11Singh HarvinderofficerAward / grant60,86563,293Form 4
2026-03-11Knight Lea DanielsofficerAward / grant111,179111,179Form 4
2026-03-11Veillon-Berteloot ChantalofficerAward / grant41,78341,783Form 4
2026-03-10McBreen Michael J.officerWithheld for tax2,35467,990Form 4
2026-03-10DAVIS ROBERT T. JR.officerWithheld for tax68774,874Form 4
2026-03-10Singh HarvinderofficerWithheld for tax60122,551Form 4
2026-03-10Mosebrook JeffreyofficerWithheld for tax34136,259Form 4
2026-03-10Singh HarvinderofficerOption exercise1,21621,350Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.